<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00640367</url>
  </required_header>
  <id_info>
    <org_study_id>SYNTHESIS EXPANSION</org_study_id>
    <nct_id>NCT00640367</nct_id>
  </id_info>
  <brief_title>Intra-arterial Versus Systemic Thrombolysis for Acute Ischemic Stroke</brief_title>
  <acronym>SYNTHESIS EXP</acronym>
  <official_title>Synthesis Expansion: A Randomized Controlled Trial on Intra-Arterial Versus Intravenous Thrombolysis in Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Niguarda Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Niguarda Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SYNTHESIS is a pragmatic multicenter randomized controlled trial (RCT), open-label, with&#xD;
      blinded follow-up aiming to determine whether loco-regional intra-arterial (IA) with&#xD;
      recombinant tissue-plasminogen activator (rt-PA) and/or mechanical devices, as compared with&#xD;
      systemic intravenous (I.V.) infusion of rt-PA within 3 hours of ischemic stroke, increases&#xD;
      the proportion of independent survivors at 3 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligibility criteria:patients with symptomatic, CT verified, acute ischemic stroke, being&#xD;
      able to initiate IV rt-PA within 3 hours and IA thrombolysis within 6 hours of stroke onset,&#xD;
      when uncertainty about appropriateness the two approaches exists as established by the&#xD;
      treating physician.&#xD;
&#xD;
      Eligible patients are randomized to receive either 0.9 mg/kg (max 90 mg) IV rt-PA (control&#xD;
      arm) or up to 0.9 mg/Kg IA rt-PA (max 90 mg) over 60 minutes into the thrombus, eventually&#xD;
      associated with clot mechanical disaggregation/dislocation or retraction/aspiration.&#xD;
      Mechanical thrombolysis is possible also without the use of rt-PA. The procedural choices of&#xD;
      the interventional neuroradiologist depend on the type of occlusion, circumstances and&#xD;
      experience.&#xD;
&#xD;
      The study is designed to detect or disprove (alpha=5% and power probability=80%) a 15%&#xD;
      absolute difference between the treatment groups in the percentage of patients with a&#xD;
      favourable outcome (Modified Rankin Scale Score = 0-1).Enrollment will be completed with 350&#xD;
      randomized patients.&#xD;
&#xD;
      Neurological deficit will be scored with NIH Stroke Scale at day 7 or discharge, or transfer&#xD;
      to another hospital, whichever occurs first.Patient's clinical condition will be again&#xD;
      evaluated by a telephone call after 90 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess whether IA thrombolysis, as compared to IV rt-PA, increases survival free of disability (modified Rankin score of zero or 1) at 3 months.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To asses whether IA thrombolysis vs.IV rt-PA 1.improves the 7 day neurological deficit; 2.is safe on the base of symptomatic intracranial hemorrhages, fatal and non-fatal stroke, death from any cause, neurological deterioration within 7 days</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Stroke</condition>
  <condition>Cerebrovascular Accident</condition>
  <arm_group>
    <arm_group_label>IA thrombolysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IA recombinant tissue plasminogen activator and/or mechanical thrombolysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV rtPA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV recombinant tissue plasminogen activator</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Alteplase IA and/or mechanical thrombolysis</intervention_name>
    <description>loca intra-arterial recombinant tissue plasminogen activator and/or mechanical thrombolysis</description>
    <arm_group_label>IA thrombolysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase IV</intervention_name>
    <description>intravenous recombinant tissue plasminogen activator</description>
    <arm_group_label>IV rtPA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sudden focal neurological deficit attributable to a stroke&#xD;
&#xD;
          -  Clearly defined time of onset, allowing initiation of intravenous treatment within 3&#xD;
             hours of symptoms onset and intra-arterial treatment within 6 hour of symptoms onset.&#xD;
&#xD;
          -  Age greater than 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disability preceding stroke consistent with a modified Rankin scale score of 2-4&#xD;
&#xD;
          -  Coma at onset&#xD;
&#xD;
          -  Rapidly improving neurological deficit&#xD;
&#xD;
          -  Seizure at onset&#xD;
&#xD;
          -  Clinical presentation suggestive of a subarachnoid hemorrhage&#xD;
&#xD;
          -  Previous history of intracranial hemorrhage&#xD;
&#xD;
          -  Septic embolism&#xD;
&#xD;
          -  Arterial puncture at a non compressible site within the previous 7 days&#xD;
&#xD;
          -  Any traumatic brain injury within the previous 14 days&#xD;
&#xD;
          -  Surgery of the central nervous system in the previous 3 months&#xD;
&#xD;
          -  Gastrointestinal hemorrhage or urinary tract hemorrhage within the previous 14 days.&#xD;
&#xD;
          -  Current therapy with intravenous or subcutaneous heparin to rise the clotting time&#xD;
&#xD;
          -  Known hereditary or acquired hemorrhagic diathesis, baseline INR greater than 1.5,&#xD;
             aPTT more than 1.5 times normal, or baseline platelet count less than 100,000 per&#xD;
             cubic millimeter&#xD;
&#xD;
          -  Baseline blood glucose concentrations below 2.75 mm/L (50 mg/dL).&#xD;
&#xD;
          -  Known contrast sensitivity.&#xD;
&#xD;
          -  Women of childbearing potential (unless pregnancy impossible) or known to be&#xD;
             breastfeeding. Uncontrolled hypertension defined by a blood pressure greater or equal&#xD;
             185 mmHg systolic or diastolic greater or equal 110 mm Hg in 3 separate occasions at&#xD;
             least 10 minutes apart or requiring continuous IV therapy.&#xD;
&#xD;
          -  Prognosis very poor regardless of therapy; likely to be dead within months.&#xD;
&#xD;
          -  Unlikely to be available for follow-up (eg, no fixed home address, visitor from&#xD;
             overseas).&#xD;
&#xD;
          -  Any other condition which local investigators feels would pose a significant hazard in&#xD;
             terms of risk/benefit to the patient, or if therapies are impracticable.&#xD;
&#xD;
        COMPUTED TOMOGRAPHIC (CT) SCAN EXCLUSION CRITERIA&#xD;
&#xD;
          -  Intracranial tumors except small meningioma&#xD;
&#xD;
          -  Hemorrhage of any degree&#xD;
&#xD;
          -  Acute infarction (since this may be an indicator that the time of onset is&#xD;
             uncorrected)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfonso Ciccone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. Ospedale Niguarda Ca' Granda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A.O. Ospedale Ca' Granda</name>
      <address>
        <city>Milan</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>March 18, 2008</study_first_submitted>
  <study_first_submitted_qc>March 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2008</study_first_posted>
  <last_update_submitted>April 24, 2014</last_update_submitted>
  <last_update_submitted_qc>April 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute ischemic stroke</keyword>
  <keyword>thrombolysis</keyword>
  <keyword>intra-arterial thrombolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

